上海医药(02607.HK) (601607.SH) 公布,近日下属常州制药厂收到美国食品药品监督管理局通知,关于利伐沙班片的简略新药申请,即美国仿制药申请,已获得批准。利伐沙班片主要用于降低非瓣膜性房颤患者卒中和全身性栓塞的风险;用于治疗和预防深静脉血栓形成;用于治疗肺栓塞;用于预防急性病患者静脉血栓栓塞等。(ha/j)(港股报价延迟最少十五分钟。沽空资料截至 2025-05-20 16:25。...
Source Link上海医药(02607.HK) (601607.SH) 公布,近日下属常州制药厂收到美国食品药品监督管理局通知,关于利伐沙班片的简略新药申请,即美国仿制药申请,已获得批准。利伐沙班片主要用于降低非瓣膜性房颤患者卒中和全身性栓塞的风险;用于治疗和预防深静脉血栓形成;用于治疗肺栓塞;用于预防急性病患者静脉血栓栓塞等。(ha/j)(港股报价延迟最少十五分钟。沽空资料截至 2025-05-20 16:25。...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.